Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Gilead Sciences vs. Biogen

TheMotleyFool

0 0

Plodding and plunging. That's maybe the best way to summarize 2019 so far for Gilead Sciences (NASDAQ: GILD) and Biogen (NASDAQ: BIIB), respectively.

Gilead Sciences continues to plod along with its stock range-bound throughout the year. The big biotech did, however, return to revenue growth after a long stretch of declining sales. Biogen, meanwhile, saw its shares plunge in March after experimental Alzheimer's disease drug aducanumab flopped in late-stage clinical testing.

Which of these biotech stocks is the better pick for long-term investors now? Here's how Gilead and Biogen stack up against each other.

Source Fool.com

Like: 0

GILD

Share